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Case presentation
A 27-year-old black woman was admitted to Harborview Medical
Center, a component of the Warren G. Magnuson Health Services
Center at the University of Washington, complaining of midepigastric
pain, chills, and sweats for the previous two days. She had been
hospitalized several times previously for similar complaints, Each time
the pain resolved spontaneously and no cause was found. The patient
also had a history of intravenous drug abuse including heroin and
amphetamines over a period of 7 years, but she denied drug use in the 2
months preceding admission. Her most recent medical evaluation was
carried out 4 months prior to the present admission. At that time her
serum creatinine was 0.9 mg/dl, BUN was 24 mg/dl, urinalysis was
negative for protein, and urine sediment was unremarkable.
Physical examination revealed a blood pressure of 160/110 mm Hg,
temperature of 38°C, and pulse of 90/mm. Multiple healed needle tracks
were present on both arms. The ocular fundi were normal. Dental
hygiene was poor. Mild, nontender cervical adenopathy was present.
The lungs were clear. A grade IlI/VI crescendo-decrescendo systolic
murmur was noted at the left sternal border radiating to the apex. The
liver was palpable 1 cm below the right costal margin, but the spleen
was not felt. Bilateral I + pretibial edema was present. No Roth spots or
splinter hemorrhages were noted.
Laboratory studies demonstrated an iron deficiency anemia, with a
hematocrit of 30% and a reticulocyte count of 2.0%. The corrected
erythrocyte sedimentation rate was 48 mm/hr. The white blood cell
count was 21,600/mm3 with 81 neutrophils, 3 bands, 10 lymphocytes, 5
monocytes, and 1 eosinophil. The platelet count was 460,000/mm3.
Hemoglobin electrophoresis was normal. Urinalysis disclosed 4+ pro-
tein with no glucose; the urine sediment contained 10 to 20 red blood
cells and 5 to 10 white blood cells per high-power field, numerous
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granular casts, and occasional red cell and fatty casts. Urine protein
excretion was 10.9 g/24 hr. Total serum protein was 7.9 g/dl with
albumin of 3.0 g/dl. There was a diffuse increase in gamma globulins.
Serum creatinine was 1.0 mg/dl; BUN, 15 mg/dl; and fasting blood
sugar, 92 mg/dl. Serum sodium, potassium, chloride, bicarbonate,
calcium, phosphate, uric acid, cholesterol, and liver function tests were
within normal limits. Antibody was present to hepatitis B core and
surface antigens, but the test for hepatitis B surface antigen was
negative. Circulating immune complexes measured by a solid phase
Clq binding assay were 27% (normal, 0%—9%). Serum C3 was 134 mg/dl
(normal, 100—200), C4 was 25 mg/dl (normal, 10—40), and CH50 was 116
units (normal, 80—160). An antinuclear antibody test was positive in a
speckled pattern at 1:10. Tests for rheumatoid factor, streptozyme, and
cryoglobulins were normal or negative. Toxic screens were negative for
narcotics and amphetamines. Ten blood cultures were sterile. Chest x-
ray and electrocardiogram were unremarkable. Echocardiography re-
vealed no valvular vegetations or thickening. Ultrasound examination
revealed the kidneys to be of normal size.
Following hospitalization, the patient's blood pressure returned to
normal, and the heart murmur disappeared following short-term treat-
ment with diuretics and propranolol. Proteinuria and hematuna persist-
ed, however, and the white blood cell count rose to 31,600/mm3 and
serum creatinine increased to 2.5 mg/dl. A percutaneous renal biopsy
revealed a diffuse proliferative glomerulonephritis with cellular cres-
cents in 50% of glomeruli. Glomeruli without crescents showed mesan-
gial thickening and increased numbers of neutrophils and macrophages
in capillary loops. Two small foci of necrosis were noted. The intersti-
tium contained a significant infiltrate of mononuclear cells without
scarring or fibrosis. Many tubules contained red blood cell or protein-
aceous casts. Immunofluorescence revealed diffuse, coarsely granular
deposits of IgG, 1gM, C3, and Clq in the mesangium and along the
capillary walls, but IgA was absent. Electron microscopy showed
extensive subendothelial and mesangial electron-dense deposits most
prominent near the mesangial waists as well as scattered electron-dense
deposits on the subepithelial surface of the capillary wall with extensive
effacement of the epithelial cell foot processes.
Following reports of the negative blood cultures, negative echocar-
diogram, and renal biopsy, an extensive search was undertaken for
other foci of infection. Dental examination revealed multiple decayed
teeth as well as two large and several small gingival abscesses. Eight
teeth were extracted, the abscesses were drained, and the patient
received a 3-week course of intravenous and oral antibiotics. At
discharge, the serum creatinine was 1.2 mg/dl, urine sediment was free
of red blood cells and red blood cell casts, and urine protein exretion
was 4 g/day. On a followup visit to the renal clinic 4 months later, the
serum creatinine was 1.1 mg/dl, and urine protein excretion was 1.9 g/
day.
Discussion
DR. WILLIAM G. COUSER (Head, Division of Nephrology,
and Professor of Medicine, University of Washington, Seattle,
Washington): Several renal lesions have been reported in
patients, such as this one, who have a history of parenteral drug
abuse. These lesions include nephrotic syndrome with focal
glomerular sclerosis [11, hepatitis B-associated membranous
nephropathy [2], vasculitis [3], interstitial nephritis [4], and
amyloidosis [5]. But this patient presents a typical picture of a
chronic postinfectious glomerulonephritis associated with gran-
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ular immune-complex deposits at mesangial, subendothelial,
and subepithelial sites. Similar deposits are seen in other
postinfectious nephropathies, such as subacute bacterial endo-
carditis and shunt nephritis as well as in diseases such as lupus
nephritis, type-I membranoproliferative glomerulonephritis
(MPGN), and severe IgA nephropathy or Henoch-SchOnlein
purpura [6]. The pyogenic gingival infection that initiated this
patient's illness probably arose from mixed flora containing
aerobic and anaerobic streptococci and other organisms. Al-
though postinfectious nephntis usually is associated with
group-A beta-hemolytic streptococci of so-called nephritogenic
serotypes, it also has been reported with non-group-A strepto-
cocci as well as with a variety of other organisms [7—9].
The association between bacterial infection and glomerulone-
phritis was first identified by Lohlein in 1907 [10]. Schick first
suggested an immune basis for glomerulonephritis after observ-
ing that nephritis following scarlet fever or tonsillitis occurs
after a time interval consistent with that seen in hypersensitivity
reactions [ii], Von Pirquet came to similar conclusions after
observing the similarity between the time course of poststrepto-
coccal nephritis and that of serum sickness in humans [12].
Support for this hypothesis was provided in the late 1950s by
the first immunofluorescence studies of human kidney tissue,
which demonstrated granular immune deposits in diseased
giomeruli in poststreptococcal glomerulonephritis and other
diseases [13]. Experimental verification of the immune basis of
nephritis following exposure to a foreign protein antigen was
provided by the pioneering studies of Germuth and Dixon in the
1950s and 1960s in acute and chronic BSA-serum sickness in
rabbits [14—17]. These investigators noted that clinical and
histologic manifestations of glomerulonephritis could be in-
duced in most rabbits ito 2 weeks following a single injection of
BSA, and that immune deposits of antigen and antibody devel-
oped at mesangial, subendothelial, and subepithelial sites just
as in the patient we are discussing [14—161 (Fig. 1). It was
further noted that the glomerular deposits developed coincident
with the appearance of circulating, soluble immune complexes
of the same antigen and antibody, and that the site of deposit
formation was related to the immune response and consequent
ratio of antigen to antibody present in the circulation [17, 18].
Thus animals with high antibody levels formed large, lattice-
like, insoluble immune complexes that were cleared rapidly by
the mononuclear phagocyte system (MPS) or were deposited in
small amounts in the giomerular mesangium [15, 161. A less
vigorous antibody response led to smaller, more soluble com-
plexes, with more deposits in the mesangium and along the
capillary wall at subendothelial sites [15—18]. Poor antibody
responders, or animals repeatedly re-injected with antigen to
maintain persistent antigen excess, developed predominantly
subepithelial deposits [16—18], Because the deposits formed
only in the presence of circulating immune complexes, and
because antigen and antibody could not be detected alone in
glomeruli by conventional immunofluorescence techniques, it
was concluded that the granular deposits and glomerulonephri-
tis resulted from the glomerular trapping of soluble immune
complexes formed in the circulation. The site of complex
localization was believed to be determined largely by the ratio
of antigen to antibody and hence the size of the lattice of the
immune complexes formed [16—18]. The giomerulus was seen
as only a passive filter in this process. This view of the
pathogenesis of immune-complex nephritis, prevalent for near-
ly two decades, was supported by a number of studies of the
fate of preformed immune complexes infused into animals
(reviewed in 19). These studies demonstrated that mesangial as
well as subendothelial deposits could be produced by circulat-
ing complex trapping. The origin of subepithelial deposits was
not clarified by these studies, however. Moreover, short-term
infusion of preformed immune complexes did not induce
glomerular disease sufficient to permit studies of how this
process caused glomerular injury, although inflammatory cell
infiltrates were sometimes seen [19]. Concepts of the mediation
of immune-complex—induced tissue damage therefore were
derived primarily from studies in experimental models of neph-
rotoxic, or anti-GBM, nephritis and were then extrapolated to
glomerular injury due to preformed immune-complex trapping
[20].
Interest in the pathogenesis of immune-complex glomerulo-
nephntis was rekindled in the late 1970s. In Heymann nephritis,
a rat model of membranous nephropathy induced by active or
passive immunization against a proximal tubular brush-border
antigen (FxlA), pretreatment with the aminonucleoside of
puromycin, an epithelial cell toxin that interferes with glycopro-
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Fig. 1. Schematic depiction of intraglomerular sites of immune-complex
formation. Subepithelial deposits such as those in postinfectious gb-
merulonephritis (1) or membranous nephropathy (2) apparently form by
local, or in-situ, mechanisms. Subendothelial (3) and mesangial (4)
deposits are usually seen together and may form locally or result from
the passive trapping of preformed immune complexes from the circula-
tion. Anti-GBM antibody deposits are in a linear pattern within the
capillary wall itself (5). The mechanism of formation, composition,
quantity, and relative accessibility of each of these deposits to circulat-
ing inflammatory cells are the major determinants of the type of lesion
produced.
The inset illustrates the three layers of the normal glomerular
capillary wall, endothelial cells (EN), GBM, and epithelial cells (EP).
The negative charge on the capillary wall results from the siaboproteins
(S) coating the endothelial and epithelial cell surfaces and the heparan-
sulfate proteoglycan (HS-PG) anionic sites in the lamina ram interna
(LRI) and externa (LRE) of the GBM. (From Ref. 44).
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tein turnover on the cell membrane, prevented the formation of
subepithelial immune-complex deposits [2 1—231. This finding
first implicated a property of the glomerulus itself in immune-
complex formation. It was then found that the deposits in the
Heymann models, previously believed to result from trapping
of circulating immune complexes containing brush-border anti-
gens [24], could be produced by antibody binding directly to an
intrinsic glomerular antigen [25, 26]. Subsequent studies have
extensively reevaluated the nature of glomerular immune-com-
plex deposits at mesangial, subendothelial, and subepithelial
sites [27, 28] (Fig. 1), and have considerably revised and
extended our understanding of how these deposits form. An
outline of the mechanisms of glomerular immune deposit forma-
tion in the order! will discuss them here is presented in Tables 1
and 2. Figure 2 illustrates the mechanisms that mediate immune
glomerular injury.
Table 1. Mechanisms of subepithelial immune-complex formation
I. In-situ immune-complex formation
A. Antibody binding to glomerular antigens
1. Heymann Antigen [25, 26, 301
2. Epithelial cell foot process antigen [38]
B. Planted nonglomerular antigens
1. Charge-dependent mechanisms
a. Cationic antigens [47—49, 62]
b. Anionic antigens [66, 801
2. Charge-independent mechanisms
a. Direct binding of antigens to capillary wall by underfined
mechanisms [36, 83]
b. IgG binding to capillary wall by immune mechanisms [84,
85]
II. Circulating immune-complex trapping
A. ? Cationic or low avidity immune complexes [65, 87, 89]
Mechanisms of subepithelial glomerular
immune-complex formation
In-situ immune-complex formation
Fixed glomerular antigens. Subepithelial immune-complex
deposits are now believed to form primarily on a local, or in-
situ, basis rather than from circulating immune-complex trap-
ping, but this mechanism may involve either insoluble fixed
renal antigens or soluble exogenous antigens. Table I lists the
mechanisms involved. The in-situ mechanism has been best
studied in the rat, where it was first shown to be responsible for
initiating subepithelial deposits in the passive Heymann nephri-
tis model [25, 26], The antigen responsible for this lesion, which
bears a striking resemblance to human idiopathic membranous
nephropathy, is now believed to be a glycoprotein with a
molecular weight of about 330 Kd (GP330) [29, 301. The antigen
is distributed along the glomerular epithelial cell membrane,
where it is localized in endoplasmic reticulum and in coated pits
[30]. Unlike deposition of anti-GBM antibody, which occurs
almost immediately [31], antibody to the epithelial cell antigen
deposits slowly for reasons that are unclear [32]. Studies of
antibodies combining with similar plasma-membrane antigens
(such as angiotensin converting enzyme) on pulmonary endo-
thelial cells or in the oolemma of rabbit oocytes [33, 34], and
studies utilizing antibody to GP330 and cultured rat glomerular
epithelial cells [35] have suggested that the interaction of
divalent antibody with such plasma membrane antigens induces
antigen redistribution and capping on the cell surface. Immune
complexes are then shed into the adjacent lamina rara externa
of the GBM and into slit pores. This distribution probably
results in the discontinuous, finely granular appearance of these
deposits. Other mechanisms may contribute to immune-com-
plex formation in Heymann nephritis. For example, Abrass and
Cohen have identified a component of the nephritogenic tubular
brush-border antigen that can localize directly in glomeruli from
the circulation and which may serve as a "planted" antigen
[36]. These workers also have described the development later
in the course of passive Heymann nephritis of a second
antibody that reacts with glomeruli but not with brush borders
[37]. Another example of a spontaneous nephropathy due to
antibody reacting with an apparently different epithelial cell
antigen has been reported in rabbits [38].
Table 2. Mechanisms of mesangial and subendothelial
immune-complex formation
In-situ i,nmune-complex formation
Glomerular antigens
Endothelial cell-membrane antigens [90]
Planted nonglomerular antigens
Charge-related localization of large cationic antigens [63]
Biochemical affinity of antigen for GBM glycoprotein [93]
Mesangial uptake of macromolecular antigens [97]
Immune-complex deposit interaction with:
I. Rheumatoid factors [103]
2. Antiidiotypic antibodies [104]
3. Circulating immune complexes 1105]
Circulating immune-complex trapping
Determinants of:
Systemic factors
I. Renal blood flow [110]
2. Mononuclear phagocyte system function [107, 108]
3. Erythrocyte CR1 receptors [109]
Glomerular factors
1. Hemodynamic changes [1111
2. Charge and permeability [78, 79]
3. Mesangial afferent and efferent limb function [61, 112]
Properties of immune complexes
1. Size [113]
2. Charge [89, 114]
3. Complement-fixing ability [109]
4. Biodegradability [99, 101].
a Numerals in brackets are reference numbers.
Since the immunogen usually utilized to elicit Heymann
nephritis is derived from a crude proximal tubular brush-border
membrane fraction, many laboratories have searched for evi-
dence of brush-border antigen or antibody to the immunogen in
human membranous nephropathy. With rare exceptions [39,
40], these studies have been negative [41, 42]. However, studies
designed to evaluate the possibility that the antibody in human
membranous nephropathy may be directed against a glomerular
epithelial cell antigen rather than against a tubular brush-border
antigen have not yet been carried out despite increasing suspi-
cion that such an autoimmune mechanism is probably operative
in this disease [43, 44].
Except for anti-GBM disease, no human equivalent of im-
mune-complex glomerulonephritis due to antibody reacting
with a fixed glomerular antigen has so far been identified.
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Fig. 2. Defined mechanisms by which glomerular im,nune-co,nplex
deposits mediate tissue injury as evidenced by increased glomerular
permeability and proreinuria are shown in solid lines. Proteinuria may
result from antibody binding to some fixed glomerular antigens (1), or
from the direct effect of complement activation (2). Complement
activation by subendothelial and mesangial deposits may attract neutro-
phils by chemotactic (C5a) or immune adherence (C3b) mechanisms (3).
Macrophages may also be attracted by immune adherence mechanisms
involving Fc receptors (4). The capacity of sensitized T cells to cause
glomerular injury by macrophage recruitment, or perhaps directly (5), is
not yet fully established and is therefore shown in dotted lines.
Similarly, the role of mesangial cells in producing glomerular injury
remains hypothetical. Activated inflammatory cells cause basement
membrane damage by release of proteases and/or reactive oxygen
species.
However, antibodies to DNA are known to be polyspecific and
reactive with shared antigenic epitopes on several structures
including polynucleotides, phospholipids, cell membranes, cy-
toskeletons, and bacteria [45]. Monoclonal anti-DNA antibod-
ies have been shown by Madaio et a! to bind directly to
glomerular structures in mice [461. Such studies support the
hypothesis that antibody binding to fixed non-GBM glomerular
antigens may contribute to some types of human immune-
complex nephritis.
Planted non-glomerular antigens. Subepithelial immune-
complex deposits also can occur in nephritis induced by exoge-
nous antigens as they do in the chronic BSA serum-sickness
models. Multiple mechanisms have now been identified that can
lead to such "planted" antigen deposits (Table 1); several
involve electrical interactions between glomerular anionic sites,
principally the negatively charged heparan-sulfate proteogly-
cans in the laminae rarae of the capillary wall (Fig. 1), and
cationic, or positively charged, immune reactants.
If chronic serum sickness is induced with BSA chemically
modified to increase the p1 from 4.5 to greater than 9.0, rabbits
develop predominantly subepithelial deposits, independent of
the immune response or of the quantity and size of circulating
immune complexes [47]. Initial localization of cationic antigen
prior to antibody binding has been demonstrated by both
immunofluorescence and radiolabeling techniques, although the
antigen does not persist and disease does not develop unless
antibody binding produces immune complexes [47—49]. More-
over, a similar lesion can be produced if one perfuses an
isolated kidney with cationic antigen followed by antibody to it,
thus establishing that the deposits are formed locally [48, 49].
The granular nature of these deposits probably results from the
tendency of anionic structures to coalesce after interaction with
cationic molecules [501, as well as from the capacity of immune
complexes formed of multivalent antigens and precipitating
antibodies to rearrange and condense into larger latticed struc-
tures visible by electron microscopy [51].
Like Heymann nephritis, the cationic BSA serum sickness
model has been suggested as a model of human membranous
nephropathy [47, 52]. Thus therapy with polycations, which
neutralize anionic sites and therefore reduce deposit formation
in cationic BSA serum sickness, has been advocated for study
in membranous nephropathy in humans 1521. As in all exoge-
nous antigen-induced nephropathies, however, some deposits
in serum sickness occur in subendothelial and mesangial sites as
well [47, 53]. Deposits in these locations are atypical of idio-
pathic membranous nephropathy, which morphologically more
closely resembles the lesion induced by the fixed-antigen mech-
anism. This distinction could have therapeutic relevance, be-
cause studies of polycation therapy in fixed antigen models of
membranous nephropathy have shown no detectable effect on
antibody deposition or on proteinuria 154].
This mechanism of cationic antigen-induced immune-com-
plex nephritis recently has been applied to studies of postinfec-
tious nephritis in humans. Vogt and colleagues have isolated
several anionic and cationic extracellular proteins from nephri-
togenic streptococci and used specific antibodies to them to
demonstrate glomerular localization of only cationic antigens in
glomerular immune deposits in 8 of 18 patients with early
poststreptococcal glomerulonephntis [55]. Evidence also has
been provided for the participation of a streptococcal cell
membrane antigen, endostreptosin, in immune deposits in pa-
tients with early poststreptococcal glomerulonephritis [56]. The
deposits also may contain antibody to an abnormal IgG, desia-
lated by the action of streptococcal neuraminidase, thereby
making it more cationic [57, 581. However, various inert
macromolecules, such as streptococcal M proteins, may be
localized in glomeruli without necessarily causing disease [59,
60]. Nonspecific uptake of circulating macromolecules is in-
creased in damaged glomeruli [61]. Immunofluorescence stud-
ies that identify putative pathogenetic agents in human glomeru-
lar immune deposits therefore must be interpreted with consid-
erable caution [62].
A second mechanism of in-situ subepithelial immune-com-
plex formation related to charge involves large cationic antigens
such as ferritin, which may first localize along the subendo-
thelial surface of capillary walls. Secondary fixation of antibody
leads to formation of large latticed subendothelial deposits [63,
64]. These complexes subsequently can dissolve and individual
reactants (or perhaps small immune complexes) can cross the
capillary wall to reform as larger immune complex aggregates in
the subepithelial space [63]. This mechanism may be operative
in diseases in which subepithelial and subendothelial deposits
coexist, as in the patient discussed here, or in patients with
severe lupus nephritis.
Although most attention has been directed at glomerular
localization of cationic antigens, anionic antigens such as native
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BSA and DNA clearly are important in producing both experi-
mental and clinical immune-complex nephritis. Two additional
charge-related mechanisms may account for the local formation
of immune-complex deposits containing anionic antigens. For
example, cationized IgG molecules can localize in glomeruli
just as other cationic proteins do [65], and antibody IgG then
can bind anionic antigen and thus initiate immune-complex
formation locally [661. The capacity of naturally occurring
cationic IgG to localize in this way is suggested by studies
demonstrating local formation of immune complexes of native
BSA (p1 4.5) and anti-BSA antibody following several alternate
perfusions of separated solutions of antigen and antibody in rat
kidneys [67]. Subsequent studies demonstrating that immune
deposits in this system form largely when the cationic antibody
fraction is used support that hypothesis (FLEUREN 0, et al,
personal communication). Anionic antigens perhaps facilitate
synthesis of such cationic antibody [68]. Experimental studies
have demonstrated facilitated deposition of cationic antibody to
both fixed and planted subepithelial antigens [69, 70], and
elution studies have suggested a predominance of cationic
antibodies in some naturally occurring models of glomerulone-
phritis [71, 72]. But elution studies must be interpreted with
particular caution, as only a fraction of the deposited antibody
is eluted, and that fraction has not been shown to be repre-
sentative of the total antibody deposited.
A second mechanism of considerable potential importance
with respect to anionic antigen localization involves initial
interaction between nonimmune cationic proteins derived from
inflammatory cells and platelets and glomerular anionic sites.
Anionic antigens may then bind electrical y to deposited cation-
ic proteins and initiate in-situ immune-complex formation.
Several cationic proteins might participate in this process,
including neutrophil cationic proteins [73], cationic products of
complement activation [74], and platelet factor IV [75]. Acetyl
glyceryl ether of phosphoryicholine (platelet activating factor,
PAF), released from several inflammatory cells during immune-
complex disease, may have similar effects by inducing release
of platelet cationic proteins and vasoactive amines, which
increase glomerular permeability and favor anionic antigen
localization [76]. Immune-complex formation within the renal
microvasculature can result in glomerular localization of plate-
let factor IV and platelet cationic proteins [77]. Enhanced
glomerular immune-complex formation with anionic antigens in
the presence of reduced capillary wall negative charge has been
demonstrated with the polycation polyethyleneimmine (PEI).
This polycation increases formation of mesangial, subendo-
thelial and subepithelial immune-complex deposits induced by
injection of anionic ferritin followed by antibody to it or by
injection of native BSA-containing immune complexes [78, 79].
Subepithelial immune-complex deposits have been produced
experimentally by the injection of cationized non-antibody IgG
followed by anionic BSA and then anti-BSA antibody [80].
Evidence for a loss of glomerular anionic sites prior to the
development of detectable glomerular immune-complex depos-
its in murine lupus nephritis suggests that such a process also
might be operative in vivo [81, 82].
Two anionic antigens, DNA (p1 4.5) and a purified tubular
brush-border antigen (p1 5.4), have been shown to bind directly
to glomeruli, apparently by charge-independent mechanisms
that have not been well defined [36, 83]. Antigen also may be
localized in a subepithelial distribution by immunologic mecha-
nisms in the form of IgG antibody to Heymann antigen (84, 851.
Finally, for immune-complex deposits formed by any of these
mechanisms to persist and cause disease at any site, the
deposits must be composed of precipitating antigen-antibody
systems and be capable of undergoing rearrangement or con-
densation into large lattice-like aggregates that can be visual-
ized by conventional immunofluorescence or electron micros-
copy [51, 86].
Circulating immune-complex trapping
The issue of whether preformed immune complexes can be
passively trapped in a subepithelial site remains controversial,
although I believe that this has not been convincingly shown to
occur. In studies reporting subepithelial localization of com-
plexes made of low-avidity antibodies [87] or non-covalently
linked immune complexes made with cationic antigens [65],
intravascular dissociation of antigen and antibody with subse-
quent in-situ immune-complex formation are likely to have
occurred [88]. Subepithelial localization of covalently linked
cationic immune complexes has been achieved in only one
study, which did not define the size of the complexes deposited
or carefully exclude small amounts of free cationic antigen.
Again, local complex formation is a possible explanation for the
results observed [89]. Charge neutralization has been suggested
to facilitate subepithelial localization of preformed immune
complexes [79].
Mesangial and subendothelial immune-complex deposits
Subendothelial deposits are not seen in the absence of
mesangial deposits, and deposits at the two sites presumably
develop by very similar mechanisms (Table 2). Diseases due to
mesangial and subendothelial immune-complex deposits in-
clude lupus and type-I MPGN as well as a variety of postinfec-
tious processes such as bacterial endocarditis, shunt nephritis,
and diseases such as that of today's patient [6]. Deposits at
mesangial and subendothelial sites can develop by in-situ
mechanisms and from circulating immune-complex trapping.
In-situ immune-complex formation
Antibody binding to fixed glomerular antigens. Little clinical
or experimental evidence currently exists for a fixed-antigen
mechanism in the development of glomerulonephritis associat-
ed with mesangial deposits. However, glomerulonephritis has
been produced with antibody to angiotensin converting en-
zyme, an antigen induced experimentally on the plasma mem-
brane of endothelial cells [90]. Antibodies to endothelial cell-
surface and Ia antigens have been reported in lupus and could
contribute to the production of subendothelial deposits and
glomerulonephritis by this mechanism [91, 92].
Planted non-glomerular antigens (Table 2). Antigen localiza-
tion in a subendothelial distribution induces in-situ immune-
complex formation and glomerulonephritis by two mechanisms.
Large cationic antigens such as ferritin, which cannot readily
penetrate the GBM, may localize by charge interaction with
anionic sites on the inner surface of the capillary wall and
produce subendothelial deposits [631. The affinity of certain
plant lectins, such as concanavalin A, for glucose and mannose
residues in capillary wall glycoproteins also can result in
glomerular localization of antigen. Injection of antibody to
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"planted" concanavalin A results in a linear-granular pattern of
subendothelial immune-complex deposits and glomerulonephri-
tis [931. Lectin-like components in some viruses may have the
potential for producing deposits by such a mechanism in
humans [43].
The mesangium is an intracapillary network of mesangial
cells and matrix which, like the subendothelial space, is contig-
uous with the circulation through a layer of endothelial cells
with fenestrae of about 44 nm [94]. It is therefore a ready
repository for a variety of circulating macromolecules including
potential antigens and preformed immune complexes. These
molecules enter the mesangial matrix and are degraded locally
by infiltrating monocytes or intrinsic mesangial cells, or they
exit via the glomerular hilus into the cortical interstitium and
renal lymph [95, 96]. This capacity of the mesangium to localize
antigens, and the nephritogenicity of in-situ immune-complex
formation within the mesangium, are well illustrated by the
studies of Mauer and coworkers [61, 97]. Like many macromol-
ecules, heat-aggregated human IgG administered intravenously
into rabbits localizes within the mesangium. To exclude the
presence of circulating antigen, rabbit kidneys containing the
IgG mesangial deposits then were transplanted into normal
rabbits before antibody to human IgG was administered. The
resultant production of IgG—anti-IgG immune complexes within
the mesangial matrix induced a focal proliferative glomerulone-
phntis much like that seen in several human renal diseases
associated with mesangial immune-complex deposits, such as
class Il-Ill lupus nephritis, IgA nephropathy, and Henoch-
Schönlein purpura [97]. In human IgA nephropathy, the IgA
deposits appear to represent polymeric IgA antibodies of muco-
sal origin directed against some as yet unidentified antigen [98,
99]. Anionic charge sites have been identified in the mesangium
[100, 101] and may play a role in the localization and persistence
of cationic antigens, although this effect is much less evident
than it is with capillary wall deposits [102].
Because subendothelial and mesangial deposits, whether
formed locally or from circulating complex trapping, are in
direct contact with immune reactants in the circulation, accre-
tion of deposits with further glomerular injury may continue by
other in-situ mechanisms, including the binding of rheumatoid
factors [1031 or antiidiotypic antibodies [104] to deposited IgG.
Immune interaction also continues between reactive antigen or
antibody binding sites in the deposits and their counterparts in
immune complexes formed in the circulation [105].
Circulating immune-complex trapping
Numerous studies have demonstrated the capacity of pre-
formed immune complexes injected intravenously to be pas-
sively trapped at mesangial and subendothelial sites (reviewed
in Ref. 19). In contrast to the nephritis produced consistently
when immune-complex deposits form in situ, however, the
passive trapping of preformed complexes produces an influx of
scavenging mononuclear cells [106] but little other histologic or
functional evidence of glomerular disease [19]. More prolonged
deposition of preformed complexes could be more productive
of tissue damage. Until this phenomenon is demonstrated,
however, the contention that glomerulonephritis can result
from the passive trapping of preformed immune complexes
must remain a hypothesis.
The factors regulating the glomerular deposition of preformed
complexes from the circulation have been extensively studied
and defined and are summarized in Table 2. They include
systemic factors, glomerular factors, and properties of the
immune complexes themselves. Systemic factors include renal
blood flow, MPS function, and erythrocyte CR1 receptors,
which collectively determine the plasma level, disappearance
kinetics, and renal delivery of immune complexes [107—110].
Glomerular factors include hydrostatic pressure and filtration
fraction, which determine the driving forces by which immune
complexes enter the capillary wall or mesangium from the
circulation [1111, charge and permeability characteristics of the
glomerulus itself [78, 79], and mesangial afferent and efferent
limb or clearing function [61, 96, 112]. Properties of the immune
complexes themselves are also important, particularly size and
the determinants of size such as concentration of antigen and
antibody, and antigen:antibody ratio, antigen valence, and
antibody class and avidity [113]. Other properties of immune
complexes such as charge, complement-fixing ability, and rela-
tive biodegradability also influence immune-complex deposi-
tion and persistence in glomeruli [89, 95, 109, 113, 114].
These same factors also influence the passive trapping of
immune complexes in a subendothelial distribution. Subendo-
thelial as well as mesangial deposits are seen when increased
quantities of large immune complexes are delivered to the
glomerulus, as can occur with a reduction in MPS capacity or
mesangial clearing function [107, 108] or, in primates, perhaps
by saturation of erythrocyte C3b (CR1) receptor function [109].
The largest and most persistent subendothelial deposits in
experimental systems have been produced with large latticed
preformed complexes made with cationized antibodies [1141.
Alterations in capillary wall charge and permeability not only
increase deposition but alter the pattern of immune-complex
deposits and may facilitate subendothelial localization of pre-
formed complexes [78, 79]. This finding may reflect changes in
the size-selective glomerular filtration barrier that accompany
charge reduction [115] or the increase in circulating immune
complex size that results from loss of free antigen in the urine.
Finally, with respect to the mechanisms of glomerular im-
mune-complex formation seen in response to exogenous anti-
gens such as infectious agents, I must reemphasize the dynamic
relationship always operative between antigen and antibody in
free and immune-complex form (Ag + Ab AgAb). The status
of this equilibrium is determined by the quantities of antigen
and antibody available for immune-complex formation, antigen
valence, the relative avidity of antibody for antigen, and the
rate of clearance of the immune complexes formed. Thus,
factors that reduce circulating immune-complex levels, such as
enhanced MPS function or plasma-exchange therapy, also
reduce levels of free antigen and antibody that may initiate in-
situ immune-complex formation. Conversely, factors that in-
crease circulating immune-complex levels, such as MPS block-
ade, also increase free circulating antigen and antibody levels.
This increment in available reactants would enhance both
circulating immune-complex deposition and, if appropriate con-
ditions existed, in-situ immune-complex formation [116]. Thus,
circulating immune complexes must be present, as they were in
the patient we are discussing, for deposits to form from
exogenous antigens by either immune-complex trapping or in-
situ mechanisms. Circulating complexes provide a reservoir for
the reactants that produce in-situ immune-complex deposits.
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Measurement of serum levels or glomerular deposits of antigen,
antibody, and immune complexes therefore cannot distinguish
between these two mechanisms of deposit formation in either
human or animal models such as serum sickness [62, 1161.
Mediation of immune-complex-induced glomerular injury
The formation of antigen-antibody complexes within the
glomerulus does not directly induce tissue injury. Rather,
damage occurs as a consequence of activation of other cellular
and humoral mediator systems. Because of the difficulty in
producing experimental glomerular injury by deposition of
preformed immune complexes, most studies of the mediation of
immune renal injury have been carried out in models of in-situ
immune-complex formation [281. As I have mentioned, the
mechanism by which immune-complex deposits form largely
determines the intraglomerular site of deposit formation (Fig.
1). In turn, the type of inflammatory mediators activated (Fig.
2), and consequently the lesion produced, are importantly
dependent on the site as well as on the composition of the
immune deposits [1171. Four mechanisms have been estab-
lished by which glomerular immune-complex deposits can
initiate tissue injury; evidence is accumulating for a fifth. These
mechanisms are illustrated schematically in Figure 2.
Direct effect of antibody deposition alone. The reaction of
IgG antibody with GBM antigens can markedly increase
glomerular permeability to protein independently of comple-
ment or inflammatory cells [1181. A similar effect has been
demonstrated with univalent and divalent fragments of IgG
antibody to the Heymann antigen on epithelial cell surfaces
[1191. This effect occurs only with antibody to certain antigenic
components of the glomerular capillary wall but not with others
[120, 121]. The effect presumably reflects an internal alteration
or distortion of the geometry of the filtration barrier and results
in altered permselectivity. It has not been demonstrated with
exogenous antigen-induced immune-complex formation in
glomeruli.
Direct effect of complement. This newly recognized form of
immune glomerular injury was first demonstrated in the passive
Heymann nephritis model of membranous nephropathy induced
by antibody reacting with a fixed subepithelial antigen. Protein-
una induced by in-situ subepithelial immune-complex forma-
tion was complement-dependent but did not involve inflamma-
tory cells [122]. A similar mechanism is operative when the
subepithelial deposits form in situ with planted exogenous
antigens [84]. Studies of passive Heymann nephritis in rats
made C6 deficient demonstrate a requirement for the CSb-9, or
membrane attack complex (MAC), portion of the complement
system for full development of proteinuria [123]. A similar
requirement for C6 also has been demonstrated in cationic
BSA-induced serum sickness [53] and in complement-depen-
dent anti-GBM nephritis in the rabbit [124]. Further support for
the membranolytic role of complement in immune glomerular
injury is provided by the observation that neoantigens of the
complement MAC are present, along with terminal complement
components, in glomerular lesions induced by complement-
dependent mechanisms but are absent in lesions in the genesis
of which complement does not participate [125, 126]. The
presence of neoantigens of the MAC in glomerular immune
deposits in human renal diseases, including lupus nephritis and
idiopathic membranous nephropathy [127, 128], suggests that a
similar mechanism may be operative in humans. The molecular
mechanism by which MAC formation and insertion into lipid
bilayers of cell membranes—or perhaps into basement mem-
branes [129]—alters the size-selective glomerular filtration bar-
rier has not yet been defined.
Complement-neutrophil—mediated glomerular injury. The
major mechanism of complement-mediated immune-complex—
induced tissue injury has long been thought to be generation of
chemotactic peptides, primarily CSa, by complement activation
[130]. The generation of C5a results in neutrophil attraction to
the site of immune deposits and, as a consequence, tissue injury
is produced by release of toxic products of neutrophil activation
adjacent to the GBM [20, 131, 132]. However, this mechanism
has been demonstrated only in certain models of anti-GBM
disease. Several observations document the importance of
neutrophils in these models. Neutrophils invade glomeruli 4 to
24 hours following anti-GBM antibody deposition in quantities
proportional to the amount of antibody deposited [131]. The
onset of nonselective proteinuna correlates with the appear-
ance of neutrophils, and the amount of proteinuna with their
number [132, 133]. Proteinuna can be diminished or abolished
by both complement and neutrophil depletion in some models
[131, 132], and it can be produced by infusing neutrophils into
neutrophil-depleted animals with antibody and complement
deposits [134]. The importance of complement and C5a genera-
tion in neutrophil-mediated disease has been inferred from the
beneficial effects of complement depletion and from the in-vitro
chemotactic properties of CSa [135]. But as I have already
mentioned, it now appears that a substantial portion of the
complement effect may involve the terminal complement sys-
tem [53, 123—126]. As shown in Figure 2, neutrophils also might
be attracted through immune-adherence mechanisms involving
C3b receptors [136] or might be attracted independently of
complement via Fc receptor interaction with deposited immu-
noglobulins [137, 138].
The mechanism of neutrophil-mediated injury has been pre-
sumed to involve proteolytic digestion of GBM by enzymes
released locally by invading neutrophils. This hypothesis is
supported by (1) the ability of neutrophil-denved proteases to
digest GBM in vitro [139, 140]; (2) the appearance of neutrophil-
derived enzymes and GBM fragments in the urine in comple-
ment-dependent glomerular injury [139—141]; and (3) the pres-
ence of neutrophil cationic proteins in glomerular deposits [73].
More recent studies have suggested a role for reactive oxygen
species (ROS) in neutrophil-mediated tissue injury [142, 143].
These ROS include hydrogen peroxide (H202), superoxide
anion (02), hydroxyl radical (OH), and singlet oxygen('02)
released during the respiratory burst by activated phagocytic
cells such as neutrophils and macrophages. Intrarenal infusion
of stimulants to ROS generation produces a glomerular neutro-
phil infiltrate and proteinuna, which can be prevented by
neutrophil depletion or by catalase, which destroys H202 [144].
Proteinuria in complement-neutrophil—dependent anti-GBM
nephntis also can be reduced by catalase [145]. Presumably
similar mechanisms are operative in macrophage-mediated
glomerular injury.
Complement-independent, cell-mediated glomerular injury.
Again, neutrophils appear to be able to mediate glomerular
injury independently of complement when Pc portions of im-
mune deposits are accessible for initiating immune adherence
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[137, 138]. This action probably would apply with subendo-
thelial and mesangial immune-complex deposits but is not seen
with subepithelial deposits, which are separated from circulat-
ing inflammatory cells by a layer of GBM [84, 122]. Macro-
phages also participate in immune-complex disease through
complement-independent mechanisms (Fig. 2). They are promi-
nent in glomeruli in several models of immune-complex nephri-
tis [146, 147] as well as in human disease [148, 149]. In addition
to immune-adherence mechanisms, several platelet-derived cat-
ionic proteins that can localize in glomeruli and facilitate
immune-complex formation also have chemotactic properties
for inflammatory cells (reviewed in Ref. 150). When immune
complexes form locally within the GBM, macrophage infiltrates
and proteinuna can be much reduced by prior irradiation or by
selective macrophage depletion [151, 1521, and can be induced
in cell-depleted animals by macrophages [1531. Macrophage
depletion also reduces proteinuria in accelerated, acute BSA
serum sickness [1521. The fact that this form of glomerular
injury is ameliorated when induced by antibody lacking the Fc
portion suggests that macrophages are recruited primarily by
immune-adherence mechanisms [1541. Other studies have sug-
gested, however, that macrophages follow an earlier T-cell
infiltrate in glomeruli and that macrophage accumulation is
reduced by T-cell depletion. The possibility thus exists of a
sensitized cell-mediated phenomenon [1551. One study has
suggested a role for non-sensitized lymphocytes, perhaps Fc-
receptor—bearing natural killer cells, in mediating a focal loss of
glomerular polyanion and proteinuria in early anti-GBM nephri-
tis [1561. This observation may represent an antibody-depen-
dent, cell-mediated cytotoxicity mechanism, which has been
well documented in experimental antitubular basement mem-
brane antibody-induced interstitial nephritis [1571.
Finally, resident glomerular mesangial cells may participate
in some types of immune glomerular disease [95, 158]. Mesangi-
al cells thus can produce a variety of potential inflammatory
mediators, including prostaglandins [159], acidic and neutral
proteases [160, 161], ROS [162], and an interleukin 1-like
cytokine [163]. Stimulants for such mesangial reactivity can
include exposure to, or endocytosis of, several circulating or
deposited immune reactants, including immune complexes,
complement components, and platelet activating factor [164,
165]. The identification of a subpopulation of mesangial cells
that bear Ia antigens, and which thus may present foreign
antigens in a genetically restricted fashion to sensitized T cells,
suggests that local cell-mediated immune reactors may occur in
the mesangium [166]. Whether these various properties of the
mesangial cell are pathogenetic in glomerular disease is not yet
established.
Specifically sensitized cells. The role of antibody-indepen-
dent cellular hypersensitivity to fixed or planted antigenic
components of glomerular immune complexes in human disease
has long been speculated on [167, 1681 but usually has been
discounted [169]. Experimental support for this mechanism is
now mounting, however. Infusion of cells sensitized to an
antigen planted in the glomerulus can induce glomerular hyper-
cellularity [170] and sometimes proteinuria [171]. Bolton and
coworkers induced glomerulonephritis by using GBM to immu-
nize bursectomized chickens unable to mount an antibody
response [1721. The authors reported transfer of this lesion with
cells alone [173], and thus provided strong evidence for the
capacity of sensitized cells to cause glomerular disease in that
species. Thus, the cellular arm of the immune response to
antigens that induce immune-complex nephritis may play a
previously unappreciated role in producing these lesions.
Summary
The patient we are discussing here had an acute glomerulone-
phritis induced by immune-complex formation in glomeruli.
The lesion apparently was related to a chronic bacterial infec-
tion. Glomerulonephritis resulted from immune-complex de-
posits formed at mesangial, subendothelial, and subepithelial
sites. Removal of the offending antigenic stimulus resulted in
clinical improvement and presumably resolution of the immune-
complex deposits. It should be apparent that the type and
severity of her glomerular disease were determined by at least
four factors: (1): The mechanism of glomerular immune-com-
plex formation. For example, formation of immune complexes
in situ in the mesangium results in a severe focal proliferative
glomerulonephritis, whereas deposition of apparently similar
quantities of the same reactants as preformed immune complex-
es induces little evidence of glomerular disease [19, 97]. (2) The
intraglomerular site of immune-complex formation. Immune
complexes formed in situ in the subepithelial space produce a
noninflammatory, complement-dependent, cell-independent
membranous glomerular lesion [84, 122], whereas the formation
of the same quantity of the same complexes within the capillary
wall, and therefore more accessible to circulating inflammatory
cells, induces a proliferative inflammatory lesion that is comple-
ment and neutrophil or macrophage mediated [117, 137, 152].
(3) The biologic properties of the deposited antibody. Subepi-
thelial deposits of complement-fixing IgG result in a marked
complement-dependent increase in glomerular capillary perme-
ability, whereas deposition of the same quantity of non—comple-
ment-fixing antibody at the same site produces no detectable
glomerular injury [1221. (4) Finally, if other factors are equal,
the greater the quantity of deposits formed, the more severe the
disease produced [32, 131].
Obviously, considerable progress has been made recently in
our understanding of the pathogenesis of immune-complex
glomerulonephritis like this patient's. But only by further study
of these mechanisms can we hope to continue to advance our
understanding of human immune-complex nephritis and there-
by acquire the capacity to modify it in a way that will be
beneficial to patients such as the one discussed here.
Questions and answers
Da. CHRISTINE ABRASS (Associate Professor of Medicine,
Division of Nephrology, University of Washington, Seattle
Veterans Administration Hospital): You have reviewed thor-
oughly the data that support the in-situ mechanism, and I think
there is little doubt that this mechanism plays an important role
in immune-complex nephritis. On the other hand, over the last
several years it has become a bandwagon that many investiga-
tors have jumped on, and experiments have been contrived to
prove its importance. Few investigators have designed experi-
ments using modern techniques to support the circulating
immune-complex mechanism. We were relatively narrow-mind-
ed for many years, accepting only the circulating immune-
complex theory. More recently, we are told to believe only the
in-situ theory. It may be more appropriate to consider that both
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of these mechanisms are operative in immune-complex
nephritis.
Da. CousEa: This is a very important point. Bandwagons
clearly develop in medicine. The relatively uncritical accept-
ance of the circulating immune-complex trapping mechanism is
an example that lasted for more than two decades. Now we risk
a similar phenomenon with respect to in-situ complex forma-
tion. Obviously, it is important that we avoid overinterpretation
of these recent studies as well. However, I also think that the
experimental evidence that in-situ immune complex formation
can reproduce the clinical and histologic features of most forms
of immune-complex nephritis in humans has now become very
strong [28, 174]. The contention that similar lesions can result
from circulating complex trapping remains unproved, although
it was suggested more than 25 years ago [16, 17]. 1 agree,
however, that more studies in this area are needed and that it is
critical that objectivity be retained when we interpret the data
that emerge.
DR. REx 0cm (Nephrology Fellow, University of Washing-
ton): In patients with glomerulonephritis, what is the clinical
role for measuring circulating immune complexes?
DR. COUSER: That is a good question. Obviously develop-
ment of techniques for measuring circulating immune complex-
es was stimulated by the thesis that they were the causative
agents in these diseases and from expectations that such
measurements would be of diagnostic and prognostic value,
With the exception of one study in lupus by Abrass et al [1751,
these expectations have generally not been fulfilled [176, 177].
In my view, the measurement of circulating immune complexes
is of no particular value in any renal disease that I am aware of.
I include lupus unless the measurements can be done with the
same frequency and intensity as they were done by Dr. Abrass
in her study [175]. However, as I discussed earlier, that does
not mean that the reactants that form glomerular deposits are
not present in circulating immune-complex form, but only that
the variables that lead to immune-deposit formation in glomeru-
Ii are not reflected in a clinically useful way by measurements of
total circulating immune-complex levels.
DR. STEVEN ADLER (Assistant Professor of Medicine, Divi-
sion of Nephrology, University of Washington, University
Hospital): Immunologic mechanisms obviously are important in
most of the acute glomerular diseases we see, but do these
mechanisms have a role in the progression of renal disease?
DR. COUSER: For several decades investigators have sought
immunologic processes such as cellular immunity to renal
antigens to account for progressive glomerulonephritis. I think
all this work can be summarized simply by saying that none
have been reproducibly found. As you point out, the immuno-
logic mechanisms I have discussed do account well for the
initiation of most forms of glomerulonephritis and, if severe
enough, lead to progressive disease. But they do not explain
progression. Although the thesis has not been proved in hu-
mans, I think the studies by Brenner and colleagues in rats have
established adaptive hemodynamic factors, particularly in-
creased intraglomerular pressures, as the most likely mecha-
nisms responsible for progressive glomerular disease [178].
Presumably these adaptive changes in glomerular pressures and
flows must exceed a threshold level to cause progressive
disease, and in turn a critical amount of filtering surface area
must be irreversibly lost during the acute phase of the disease
for this to occur. Humans might be less susceptible to these
changes than are rats, and other factors are likely to be
important as well. However, there is little evidence at present
to implicate immune mechanisms in this process.
DR. JEROME P. KASSIRER: It always has been puzzling to me
that some forms of immune-complex disease are spontaneously
reversible and others are not. For example, in poststreptococ-
cal glomerulonephritis the patient has a severe immune reaction
accompanied by a severe reduction in GFR, yet recovery is
often rapid and complete. By contrast, the patient with lupus
who also has severe immunologic damage usually doesn't get
better even with aggressive therapy. What is the explanation for
this difference?
DR. CousER: I think lupus is probably not a good example
because in lupus there is an ongoing autoimmune process,
whereas in poststreptococcal nephritis the disease is usually
self-limited even without therapy. Recovery depends on how
much the initial decrease in renal function reflects reversible, or
functional, factors rather than irreversible structural changes
such as necrosis, sclerosis, and fibrosis. Postinfectious glomer-
ulonephritis may be quite analogous to models of acute nephri-
tis studied experimentally, in which the decreased GFR is
consequent to changes in glomerular plasma flow and ultrafll-
tration coefficient (IU) apparently reflecting hemodynamic con-
sequences of complement activation and loss of surface area
due to inflammatory cell infiltrates [179, 180]. Because these are
largely functional changes, they may be reversed spontaneously
or by appropriate therapy before structural damage occurs. In
other forms of acute glomerulonephritis, the initial process may
be severe enough to produce irreversible structural damage so
that recovery is not possible, or it occurs only accompanied by
adaptive hemodynamic changes sufficient to result in progres-
sive disease [181]. Reversibility depends on the type and
severity of the initial lesion rather than on the mechanism that
produced it.
DR. RICHARD JOHNSON (Nephrology Fellow, University of
Washington): Are there any factors that might predispose
certain individuals over others to the development of postinfec-
tious glomerulonephritis?
DR. C0usER: Yes, there clearly are. For example, in large
populations of patients exposed to the same nephritogenic
streptococcus, some patients have no disease, some have
subclinical disease, and some have severe glomerulonephritis
[182]. Some of this variation must relate to the amount and
duration of antigenic exposure. However, much of the variation
is also related to host genetic factors that determine the immune
response to a particular antigen [183]. The influence of immuno-
genetic factors on severity and prognosis has been well estab-
lished by familial and genetic studies for several glomerular
diseases [183—185]. In poststreptococcal glomerulonephritis,
associations have been noted with HLA-D and -DR antigens in
some studies [186, 187]. Although it may be difficult and
expensive to carry out, the importance of immunogenetic
factors to the severity and outcome of glomerulonephritis is
now sufficiently well established, so this variable should be
accounted for in designing randomized prospective treatment
studies.
DR. MICHAEL R. KELLY (Clinical Professor of Medicine,
University of Washington, Swedish Hospital): In clinical
nephrology, we usually regard the C3 level as important in
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helping to make a diagnosis of postinfectious glomerulonephri-
tis. In this patient, complement levels were normal. Would you
comment on the value of C3 measurements in these kinds of
patients?
Da. COUSER: In classic poststreptococcal glomerulonephri-
tis, levels of complement as measured by C3, or total hemolytic
complement, are reduced acutely in approximately 90% of
patients, so these measurements are relatively sensitive in
making a diagnosis [188—190]. However, cases of apparently
clinically typical acute poststreptococcal nephritis with normal
complement levels have been described [191, 192]. The pres-
ence of hypocomplementemia is obviously not specific for
poststreptococcal nephritis, because it also can be seen in other
postinfectious nephritides, shunt nephritis, membranoprolifera-
tive glomerulonephritis, lupus, and certain inherited comple-
ment deficiencies associated with nephritis [190]. In glomerulo-
nephritis following nonstreptococcal bacterial infections such
as that probably in this patient, hypocomplementemia is less
common. It is present in only approximately 50% of patients
with nephritis due to bacterial endocarditis [193], and often is
absent in nephritis associated with visceral abscesses [194].
Serum complement levels must be interpreted in the context of
the rest of the clinical and laboratory findings.
DR. DAVID LOVETT (Assistant Professor of Medicine, Divi-
sion of Nephrology, University of Washington, Seattle Veter-
ans Administration Hospital): You have emphasized the role of
immune complexes formed in situ in initiating complement
activation. Is there evidence for nonimmune local complement
activation in the absence of immune deposits, and what role
might such a process play in glomerular disease?
DR. COUSER: Yes, there are examples of glomerular disease
such as type-TI membranoproliferative glumerulonephritis, late
stages of postinfectious nephritis, and others in which deposits
of complement components can be seen in the absence of
immune deposits [5, 196]. Furthermore, complement compo-
nents and membrane attack complex neoantigens are often
associated with structural glomerular lesions such as sclerosis,
fibnn caps, and PAS-positive deposits in diabetes, etc. [128].
Some of these deposits might be epiphenomena reflecting
complement activation by damaged kidney cells, as we have
shown in vitro [197]. However, there is now substantial evi-
dence that the C5b-9 portion of complement can have a non-
lytic effect on cell membranes and can result in increased
production of several inflammatory mediators [198]. Your own
studies and those of Dr. Adler have shown increased produc-
tion of proteases, prostanoids, interleukin 1-like cytokines, and
reactive oxygen species by mesangial cells in response to C5b-9
without immune deposits [165, 199]. The potential role of
resident glomerular cells in mediating glomerular disease and of
complement in stimulating that process is obviously a fruitful
area for future research.
DR. KASSIRER: Do you think it will be possible to tailor our
treatment to the specific immunologic mechanism responsible
for glomerular injury?
DR. COUSER: Yes, I do. Unfortunately, patients do not come
to our attention until they already have significant disease, so
prevention is difficult, although much progress is being made in
reducing the incidence of poststreptococcal glomerulonephritis
in this country. However, as I mentioned earlier, a critical
determinant of outcome in these diseases is how successful we
can be in preventing irreversible tissue damage during the acute
phase of the disease. Clarification of the mechanisms involved
in mediating specific types of glomerular immune injury such as
terminal complement components, macrophages, sensitized
cells, reactive oxygen species, etc. does afford the potential for
directed therapeutic interventions that may minimize or prevent
further tissue damage once an accurate diagnosis has been
made.
DR. THERESA RATTAZZI (Clinical Assistant Professor of
Medicine, University of Washington, Valley General Hospital):
If immunologic mechanisms play a role in the initiation of
glomerulonephritis but not in the progression of the disease,
what is the role of steroids in treating glomerular disease and
why do we use them?
DR. CousEa: The answer to why we use steroids probably
derives largely from their dramatic effect in minimal-change
nephrotic syndrome and the hope, which has largely been
unfulfilled, that they would be similarly beneficial in other
glomerular diseases, which are now known to be mediated by
entirely different mechanisms. However, steroids do appear to
be of benefit in several acute inflammatory forms of glomerulo-
nephritis such as lupus nephritis [200] and idiopathic, rapidly
progressive glomerulonephritis [201]. The mechanism for their
beneficial effects in these diseases is unknown, although the
accumulating evidence for a role for cell-mediated immunity in
glomerulonephritis, which I have already reviewed, is one
attractive possibility. A short-term course of steroids also
appears to be beneficial in slowing the rate of progression of
certain chronic glomerular diseases such as membranous
nephropathy [202] and perhaps focal glomerular sclerosis (Un-
published data, Collaborative study of adult glomerular dis-
ease, C. H. Coggins, Director). In these diseases the mecha-
nism of the steroid effect is even less clear but may be on
nonimmune factors that influence progression rather than on
immune factors that initiated the diseases.
Reprint requests to Dr. W. Couser, Division of Nephrology, RM-11,
School of Medicine, University of Washington, Seattle, Washington
98195, USA
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